Structure and properties of pharmacologically active polymers
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Although the concept of using pharmacologically active macromolecular compounds as drugs is still regarded with much skepticism for both theoretical and practical reasons, interest in this field has grown in recent years because of the opportunity to take advantage of the specific properties of polymeric materials. For low molecular weight drugs, changes in structure often lead to a loss of specific activity. On the other hand, the properties of macromolecular drugs depend on the structure of the polymer used and this can be varied over a wide range by the incorporation of comonomer units, by the application of polymer‐analogous reactions, or by related structural changes. A new model is presented for pharmacologically active polymers which incorporates the possibility for continuous variation in (a) solubility and toxicity, (b) fixation and removal of active material, and (c) body distribution. Using the new model as a guide, examples of the synthesis and study of the biological activity of various macromolecular drugs are presented in order to emphasize the importance of this cooperative effort between polymer research and therapeutic problems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug-polymer conjugates were introduced in the early work by Helmut Ringsdorf in 1970s to improve drug solubility, toxicity, and body biodistribution, which was followed by extensive studies on the development of drug-polymer conjugates [143, 144].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [144]
Citations
Cites
de Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Chang, T. M. S. (1964) · Science · doi:10.1126/science.146.3643.524 · Cited by 1,011
Lysosomes in Biology and Pathology
Lagunoff, D. (1974) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1974.03230160059035 · Cited by 887
AN EXAMINATION OF THE CYTOTOXIC EFFECTS OF SILICA ON MACROPHAGES
Allison, A. C., Harington, J. S., & Birbeck, M. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.124.2.141 · Cited by 871
FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE
Boneu, B., Abbal, M., Plante, J., & Bierme, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92650-1 · Cited by 716
de Duve, C. (2008) · Novartis Foundation Symposia · doi:10.1002/9780470715314.ch1 · Cited by 473
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization
Kopeček, J., & Baẑilová, H. (1973) · European Polymer Journal · doi:10.1016/0014-3057(73)90063-3 · Cited by 300
Ryser, H. J.-P. (1968) · Science · doi:10.1126/science.159.3813.390 · Cited by 288
Research works printed but not linked: 20
- Lee H., 1971, Handbook for Surgery and Artificial Organs
- Kabaiwanow W., 1972, Plaste Kaut., 19, 886
- Wessel W., 1971, Arzeim. Forsch., 21, 1468
- Ryser H. J. P., 1970, Proc. Fourth Int. Cong. Pharm., 3, 96
- 1965, Silikose Forsch., 6, 213
- Ferruti P., 1966, Med. Lav., 57, 481
- V.Hofmann dissertation University of Mainz 1975.
- Burger A., 1970, Medicinal Chemistry, 1185
- Donaruma L. G., 1974, Prog. Polym. Sci., 4, 18
- G.Franzmann dissertation University of Mainz 1975.
- H.Morawetzet al. in press.
- Ringsdorf H., 1967, Strahlentherapie, 132, 627
- Busch H., 1961, Cancer Res., 21, 271
- H.Ritter dissertation University of Mainz 1975.
- M.Przybylski dissertation University of Mainz 1975.
- Jacob S. W., 1971, Dimethylsulfoxide
- V.Hofmann H.Ringsdorf andG.Muacevic Makromol. Chem. in press.
- Jacques P. J., 1966, Rev. Quest. Sci., 27, 99
- Jacques P. J., 1969, Lysosomes in Biology and Pathology, 395
- Szekerke M., 1972, Neoplasma, 19, 211
Cited by
Items 301–400 of 1,000
Duncan, R. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1358729 · Cited by 61
“[15,16]), the Helmut Ringsdorf [17] hypothesis for polymer drug conjugate design, and Tom Connors, who always gave an objective perspective (no-nonsense scientific interrogation) of cancer research and anticancer drug development (Table 1).”
BackgroundClinical Applications of Targeted Nanomaterials
Kumar, A., Shahvej, S., Yadav, P. K., Modi, U., Yadav, A. K., Solanki, R., & Bhatia, D. D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030379 · Cited by 60
“The approach, known as Ringsdorf’s model, had a polymeric backbone, a linker for drug conjugation to the backbone, a drug, and a targeting group [30,31].”
Polymer-drug conjugates: recent progress on administration routes
Pang, X., Yang, X., & Zhai, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.912779 · Cited by 62
“Until the mid1970s, a clear analysis of a complete polymer-conjugated drug delivery system was first proposed by Ringsdorf [5].”
BackgroundPolymeric drug delivery systems for intraoral site‐specific chemoprevention of oral cancer
Desai, K. G. H. (2017) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33943 · Cited by 59
Systemic therapies for hepatocellular carcinoma
Palmer, D. H., Hussain, S. A., & Johnson, P. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.12.1555 · Cited by 60
“Water soluble polymers can be modified with a drug and a targeting molecule to achieve this goal [71].”
BackgroundEfficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs
Alven, S., & Aderibigbe, B. A. (2020) · Nanomaterials · doi:10.3390/nano10081556 · Cited by 60
“The concept of these nanocarriers was first proposed by Helmut Ringsdorf in 1975 [94].”
BackgroundDesigning Natural Polymer-Based Capsules and Spheres for Biomedical Applications—A Review
Sharma, K. N., Porat, Z., & Gedanken, A. (2021) · Polymers · doi:10.3390/polym13244307 · Cited by 56
Goto, M., Yura, H., Chia-Wun, C., Akira, K., Shinoda, T., Atsushi, M., Kojima, S., Kobayashi, K., & Akaike, T. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90169-4 · Cited by 55
Novel polysaccharide hydrogels: characterization and properties
Magnani, A., Rappuoli, R., Lamponi, S., & Barbucci, R. (2000) · Polymers for Advanced Technologies · doi:10.1002/1099-1581(200008/12)11:8/12<488::aid-pat995>3.0.co;2-5 · Cited by 53
Dingels, C., Müller, S. S., Steinbach, T., Tonhauser, C., & Frey, H. (2012) · Biomacromolecules · doi:10.1021/bm3016797 · Cited by 54
Facile synthesis of drug-conjugated PHPMA core-crosslinked star polymers
Tucker, B. S., Getchell, S. G., Hill, M. R., & Sumerlin, B. S. (2015) · Polymer Chemistry · doi:10.1039/c5py00497g · Cited by 53
Block copolymer prodrugs: Synthesis, self‐assembly, and applications for cancer therapy
Dutta, D., Ke, W., Xi, L., Yin, W., Zhou, M., & Ge, Z. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1585 · Cited by 57
Torchilin, V. P. (1987) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(87)90068-8 · Cited by 52
Cho, E., & Jung, S. (2015) · Molecules · doi:10.3390/molecules201019620 · Cited by 51
“In 1975, the concept of polymer-drug conjugates was introduced for the first time for the delivery of hydrophobic drugs to their sites of action [117].”
BackgroundBridging cancer biology and the patients' needs with nanotechnology-based approaches
Fonseca, N. A., Gregório, A. C., Valério-Fernandes, Â., Simões, S., & Moreira, J. N. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.002 · Cited by 58
“The combination of Ringsdorf’s vision of the ideal polymer chemistry for drug conjugation [58] and the realization by De Duve that the endocytic pathway might be useful for”
BackgroundTemperature‐Mediated Regulation of Enzymatic Activity
Cao, Y., & Wang, Y. (2016) · ChemCatChem · doi:10.1002/cctc.201600406 · Cited by 52
Zheng, L., Wang, Y., & Gao, W. D. (2019) · Open Chemistry · doi:10.1515/chem-2019-0009 · Cited by 51
Jagdale, S. K., Agarwal, B., Dixit, A., & Gaware, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128697 · Cited by 53
Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections
Ιωάννου, Π., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13020121 · Cited by 53
“…of nanotechnology in medicine have been developed in the last decades, such as the development of liposomes [14,15], polymer-drug conjugates [16], DNA-drug complexes [17], polymer nanocapsules [18,19], antibody-drug conjugates [20], albumin-drug conjugates [21], polymer-protein conjugates…”
BackgroundXu, X., Smith, A. E., & McCormick, C. L. (2009) · Australian Journal of Chemistry · doi:10.1071/ch09255 · Cited by 53
Liu, Z., Wang, Y.-T., & Zhang, N. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.689284 · Cited by 51
“Since the concept of “polymeric prodrug” was first proposed by Ringsdorf in 1975 [7], many polymer--protein and polymer--drug conjugates have entered the clinical use or the clinical trial stage (Table 1).”
BackgroundSoluble polymers for lectin-mediated drug targeting
Seymour, L. W. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90007-8 · Cited by 49
Przybylski, M., Fell, E., Ringsdorf, H., & Zaharko, D. S. (1978) · Die Makromolekulare Chemie · doi:10.1002/macp.1978.021790707 · Cited by 57
Self-citationTargeting of drugs and drug carriers within the cardiovascular system
Torchilin, V. P. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00042-6 · Cited by 48
Andisheh, F., Oroojalian, F., Shakour, N., Ramezani, M., Shamsara, J., Khodaverdi, E., Nassirli, H., Hadizadeh, F., & Alibolandi, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120822 · Cited by 47
Wang, G., Su, Y., Chen, X., Zhou, Y., Huang, P., Huang, W., & Yan, D. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.01.026 · Cited by 66
“that is stable in the blood to form polymer-drug conjugate, also called polymeric prodrug, which was first reported by the seminal work of Ringsdorf in 1975 [9].”
BackgroundRevolutionary Impact of Nanodrug Delivery on Neuroscience
Khanbabaie, R., & Jahanshahi, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912804143513 · Cited by 42
72/74As-labeling of HPMA based polymers for long-term in vivo PET imaging
Herth, M. M., Barz, M., Jahn, M., Zentel, R., & Rösch, F. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.092 · Cited by 51
Revolutionary Impact of Nanodrug Delivery on Neuroscience
Khanbabaie, R., & Jahanshahi, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912804499456 · Cited by 51
Studies on the interaction of DNA and water‐soluble polymeric Schiff base–nickel complexes
Xiao, Y., & Zhan, C. (2002) · Journal of Applied Polymer Science · doi:10.1002/app.10000 · Cited by 47
Functional Polymers with Biologically Active Groups
Vogl, O., & Tirrell, D. A. (1979) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337908068110 · Cited by 47
Heart-Targeted Nanoscale Drug Delivery Systems
Liu, M., Li, M., Wang, G., Liu, X., Liu, D., Peng, H., & Wang, Q. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.1894 · Cited by 52
N,N-Diallylglycidylamine: A Key Monomer for Amino-Functional Poly(ethylene glycol) Architectures
Reuss, V. S., Obermeier, B., Dingels, C., & Frey, H. (2012) · Macromolecules · doi:10.1021/ma300292m · Cited by 46
Georgieva, R. T., Tsevi, R., Kosev, K., Kusheva, R., Balgjiska, M., Petrova, R., Tenchova, V., Gitsov, I., & Troev, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020309o · Cited by 46
TRANSPORT STUDIES ON MACROMOLECULES USED AS DRUG CARRIERS
Kulkarni, P. V., Rajur, S. B., Antich, P. P., Aminabhavi, T. M., & Aralaguppi, M. I. (1990) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/07366579008050915 · Cited by 46
The renal excretion and retention of macromolecules: The chemical structure effect
Rypáček, F., Drobnik, J., Chmelar, V., & Kálal, J. (1982) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00584298 · Cited by 46
Drug and protein delivery by polymer conjugation
Grigoletto, A., Maso, K., Mero, A., Rosato, A., Schiavon, O., & Pasut, G. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.08.006 · Cited by 49
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 46
Teixeira, S., Carvalho, M. A., & Castanheira, E. M. S. (2022) · Biomedicines · doi:10.3390/biomedicines10020486 · Cited by 48
STIMULI-SENSITIVE PARTICLES FOR DRUG DELIVERY
Grainger, S. J., & ElSayed, M. E. H. (2010) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814295680_0008 · Cited by 45
Davaran, S., & Entezami, A. A. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(96)01614-8 · Cited by 45
Ferruti, P., Tanzi, M. C., Rusconi, L., & Cecchi, R. (1981) · Die Makromolekulare Chemie · doi:10.1002/macp.1981.021820807 · Cited by 45
Artificial intelligence assists nanoparticles to enter solid tumours
Nuhn, L. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01382-7 · Cited by 45
Tauro, J. R., Lee, B.-S., Lateef, S. S., & Gemeinhart, R. A. (2008) · Peptides · doi:10.1016/j.peptides.2008.06.021 · Cited by 44
“Following the introduction by Ringsdorf of polymer– prodrugs [23], various polymeric anticancer drug conjugates,”
InfluentialGueugnon, F., Denis, I., Pouliquen, D., Collette, F. M., Delatouche, R., Héroguez, V., Grégoire, M., Bertrand, P., & Blanquart, C. (2013) · Biomacromolecules · doi:10.1021/bm400516b · Cited by 44
Mei, L., Liu, Y., Xia, C., Zhou, Y., Zhang, Z., & He, Q. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00979 · Cited by 44
Li, D., Feng, X., Chen, L., Ding, J., & Chen, X. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00856 · Cited by 44
Bioconjugation in Drug Delivery: Practical Perspectives and Future Perceptions
Elzahhar, P. A., Belal, A. S. F., ElAmrawy, F., Helal, N. A., & Nounou, M. I. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9516-5_11 · Cited by 47
Wamsley, A., Jasti, B., Phiasivongsa, P., & Li, X. (2003) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.11020 · Cited by 43
Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
Vicent, M. J., Greco, F., Nicholson, R. I., Paul, A., Griffiths, P. C., & Duncan, R. (2005) · Angewandte Chemie · doi:10.1002/ange.200462960 · Cited by 45
Micellar Delivery System for Dequalinium—A Lipophilic Cationic Drug with Anticarcinoma Activity
Weissig, V., Lizano, C., & Torchilin, V. P. (1998) · Journal of Liposome Research · doi:10.3109/08982109809035542 · Cited by 45
Controlled Release of Drug Model from N‐(2‐Hydroxypropyl)‐methacrylamide Copolymers
Kopec̆ek, J., Rejmanová, P., Duncan, R., & Lloyd, J. B. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb18393.x · Cited by 43
From Phage Display to Dendrimer Display: Insights into Multivalent Binding
Bastings, M. M. C., Helms, B. A., van Baal, I., Hackeng, T. M., Merkx, M., & Meijer, E. W. (2011) · Journal of the American Chemical Society · doi:10.1021/ja110700x · Cited by 46
Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy
Li, D., Su, T., Ma, L., Yin, F., Xu, W., Ding, J., & Li, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112367 · Cited by 43
Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs
Boztepe, T., Castro, G. R., & León, I. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120788 · Cited by 47
Hirano, T., Klesse, W., & Ringsdorf, H. (1979) · Die Makromolekulare Chemie · doi:10.1002/macp.1979.021800438 · Cited by 42
Self-citationHirano, T., Ohashi, S., Morimoto, S., Tsuda, K., Kobayashi, T., & Tsukagoshi, S. (1986) · Die Makromolekulare Chemie · doi:10.1002/macp.1986.021871208 · Cited by 44
Yang, J., Yang, Z., Wang, H., Chang, Y., Xu, J., & Zhang, X. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202402291 · Cited by 41
Targeted polymer-drug conjugates: Current progress and future perspective
Xu, H., Ma, H., Yang, P., Zhang, X., Wu, X., Yin, W., Wang, H., & Xu, D. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.10.001 · Cited by 41
Synthesis and pH-responsive properties of pseudo-peptides containing hydrophobic amino acid grafts
Chen, R., Eccleston, M., Yue, Z., & Slater, N. K. H. (2009) · Journal of Materials Chemistry · doi:10.1039/b902822f · Cited by 43
Jain, R. D., Dandekar, P. P., Loretz, B., Melero, A., Stauner, T., Wenz, G., Koch, M., & Lehr, C. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.030 · Cited by 41
Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Kunjachan, S., Jayapaul, J., Mertens, M. E., Storm, G., Kiessling, F. M., & Lammers, T. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112799436302 · Cited by 41
Schacht, E. H., Buys, L., Vermeersch, J., & Remon, J. P. (1984) · Journal of Controlled Release · doi:10.1016/0168-3659(84)90019-1 · Cited by 41
Cho, J.-K., Chun, C., Kuh, H., & Song, S. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.008 · Cited by 40
Kong, Y. W., & Dreaden, E. C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.879988 · Cited by 40
“…and utility, Jatzkewitz ’ s innovation went largely unnoticed until the mid 1970s when it was revived by Ringsdorf, Kopecek, and Duncan, among others, who championed the notion that these novel macromolecules could enhance the suboptimal activity of various pharmaceuticals (Ringsdorf, 1975).”
BackgroundCytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics
Říhová, B., Kovář, L., Kovář, M., & Hovorka, O. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.10.006 · Cited by 40
Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier
Huang, W., Wang, W., Wang, P., Zhang, C., Tian, Q., Zhang, Y., Wang, X., Cha, R., Wang, C., & Yuan, Z. (2011) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-011-4262-2 · Cited by 42
“therapeutic drugs, such as doxorubicin (DOX), camptothecin and paclitaxel, cause serious systemic toxicity, induce multidrug resistance, and suffer from rapid phagocytic and renal clearance, which limit their clinic application [1, 2].”
BackgroundPolymer-drug conjugates: manipulating drug delivery kinetics using model LCST systems
Shah, S. S., Wertheim, J. A., Wang, C. T., & Pitt, C. G. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(96)01550-7 · Cited by 40
Drug delivery systems: polymers and drugs monitored by capillary electromigration methods
Simó, C., Cifuentes, A., & Gallardo, A. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00430-6 · Cited by 40
Doxorubicin-Conjugated Nanoparticles for Potential Use as Drug Delivery Systems
Mun, E. A., Zhaisanbayeva, B. A., Imantay, A., & Mashurov, N. (2025) · Nanomaterials · doi:10.3390/nano15020133 · Cited by 41
“These components are organized through methods like block or statistical copolymerization [51].”
Polysaccharide-based materials in macromolecular prodrug design and development
Hussain, M. A., Abbas, K., Jantan, I., & Bukhari, S. N. A. (2016) · International Materials Reviews · doi:10.1080/09506608.2016.1209617 · Cited by 40
Müller, B., Zhdanov, A. V., Borisov, S. M., Foley, T., Okkelman, I. A., Tsytsarev, V., Tang, Q., Erzurumlu, R. S., Chen, Y., Zhang, H., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201704598 · Cited by 39
Troev, K. D., Tsacheva, I., Koseva, N. S., Georgieva, R. T., & Gitsov, I. (2007) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.21906 · Cited by 39
Barz, M., Armiñán, A., Canal, F., Wolf, F. K., Koynov, K., Frey, H., Zentel, R., & Vicent, M. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.024 · Cited by 44
Bioactive Polymeric Systems, An Overview
Gebelein, C. G. (1985) · Springer eBooks · doi:10.1007/978-1-4757-0405-1_1 · Cited by 39
Yuan, F., Qin, X., Zhou, D., Xiang, Q., Wang, M.-T., Zhang, Z., & Huang, Y. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.028 · Cited by 39
Polyphophazenes as anti-cancer drug carriers: From synthesis to application
Akram, M. A., Wang, L., Yu, H., Amer, W. A., Khalid, H., Abbasi, N. M., Chen, Y., Ul-Abdin, Z., Saleem, M., & Tong, R. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.07.009 · Cited by 38
Functionalization of Cationic Polymers for Drug Delivery Applications
Tabujew, I., & Peneva, K. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782620105-00001 · Cited by 45
Shining Light on Polymeric Drug Nanocarriers with Fluorescence Correlation Spectroscopy
Schmitt, S., Nuhn, L., Barz, M., Butt, H., & Koynov, K. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202100892 · Cited by 40
Drug Delivery Systems: 3A. Role of Polymers in Drug Delivery
Ranade, V. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03432.x · Cited by 48
Encapsulation of Ru(II) Polypyridine Complexes for Tumor-Targeted Anticancer Therapy
Karges, J. (2023) · BME Frontiers · doi:10.34133/bmef.0024 · Cited by 37
“This approach involves linking the drug covalently to a hydrophilic polymer [111].”
BackgroundA journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles
Vauthier, C. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1588280 · Cited by 40
“Few drugs were associated with proteins such as antibodies or with DNA serving as lysosomotropic carriers (see [63] for references) or coupled with synthetic hydrosoluble polymers (see [64,65] for references).”
BackgroundSong, Q., Yang, J., Hall, S. C. L., Gurnani, P., & Perrier, S. (2019) · ACS Macro Letters · doi:10.1021/acsmacrolett.9b00538 · Cited by 37
“Conjugating synthetic polymers to biomolecules has become a highly prolific field of research since the concept was introduced by Ringsdorf in 1975.([1]) Non-naturally modulating these biomolecules with synthetic polymers leads to changes of their structural and functional properties, enabling chemists to tune their i…”
BackgroundMultivalent Probes in Molecular Imaging: Reality or Future?
Böhmer, V. I., Szymański, W., Feringa, B. L., & Elsinga, P. H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.12.006 · Cited by 38
Barz, M., Wolf, F. K., Canal, F., Koynov, K., Vicent, M. J., Frey, H., & Zentel, R. (2010) · Macromolecular Rapid Communications · doi:10.1002/marc.201000090 · Cited by 41
A hindsight reflection on the clinical studies of poly( l ‐glutamic acid)‐paclitaxel
Zhao, J., Koay, E. J., Li, T., Wen, X., & Li, C. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1497 · Cited by 37
Dendritic systems in drug delivery applications
Jain, N. K., & Asthana, A. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.5.495 · Cited by 44
“Ringsdorf in 1975 provided a rational model for pharmacologically active macromolecules, specifically the utilisation of polymers as macromolecular carriers of drugs [84] .”
BackgroundHOVORKA, O., Etrych, T., Šubr, V., Strohalm, J., Ulbrich, K., & Říhová, B. (2006) · Journal of drug targeting · doi:10.1080/10611860600833591 · Cited by 37
“Although the idea of highly sophisticated polymeric systems is quite old (Ringsdorf 1975), only few of them have reached the preclinical and clinical testing (Kerr et al. 1998; Julyan et al. 1999; Řı́hová et al. 2003).”
BackgroundMultifunctional Synthetic Poly( l -Glutamic Acid)–Based Cancer Therapeutic and Imaging Agents
Melancon, M. P., & Li, C. (2011) · Molecular Imaging · doi:10.2310/7290.2011.00007 · Cited by 39
“In the mid-1970s, Ringsdorf proposed a model for a polymer-drug conjugate that could enhance the delivery of an anticancer drug to a tumor.(16) In this model, a polymeric carrier is conjugated with a drug to enhance its pharmacologic properties, and a homing ligand can also be attached for active targeting (Figure 1A).”
BackgroundKrinick, N. L., Říhová, B., Ulbrich, K., Strohalm, J., & Kopec̆ek, J. (1990) · Die Makromolekulare Chemie · doi:10.1002/macp.1990.021910412 · Cited by 36
Guo, H., & Mi, P. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1988 · Cited by 37
Kumirska, J., Mirko, X., Czerwicka, M., Kaczyski, Z., Bychowska, A., Brzozowski, K., Thming, J., & Stepnowski, P. (2011) · InTech eBooks · doi:10.5772/13481 · Cited by 44
“The concept of polymer-drug conjugates for delivering hydrophobic, small molecular drugs to their site of action was first propounded by Ringsdorf in 1975 (Ringsdorf, 1975).”
BackgroundEffect of solvents on the RAFT polymerization of N-(2-hydroxypropyl) methacrylamide
Pan, X., Zhang, F., Choi, B., Luo, Y., Guo, X., Feng, A., & Thang, S. H. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.03.016 · Cited by 35
Anticancer Polymers via the Biginelli Reaction
Li, Y., Tan, T., Zhao, Y., Wei, Y., Wang, D., Chen, R., & Tao, L. (2020) · ACS Macro Letters · doi:10.1021/acsmacrolett.0c00496 · Cited by 35
Wu, H., Wang, H., Qi, F., Xia, T., Xia, Y., Xu, J., & Zhang, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c09823 · Cited by 35
(2015) · Elsevier eBooks · doi:10.1016/b978-0-08-100092-2.00002-3 · Cited by 35
Recent Advances in the Application of ATRP in the Synthesis of Drug Delivery Systems
Szewczyk‐Łagodzińska, M., Plichta, A., Dębowski, M., Kowalczyk, S., Iuliano, A., & Florjańczyk, Z. (2023) · Polymers · doi:10.3390/polym15051234 · Cited by 36
Growth of Polyelectrolyte Complex Nanoparticles: Computer Simulations and Experiments
Starchenko, V., Müller, M., & Lebovka, N. (2008) · The Journal of Physical Chemistry C · doi:10.1021/jp800581y · Cited by 35
Development of Cell-Specific Targeting Systems for Drugs and Genes
Nishikawa, M. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.195 · Cited by 37
New functional polyamides derived from citric acid and L‐lysine: Synthesis and characterization
Boustta, M., Huguet, J., & Vert, M. (1991) · Makromolekulare Chemie Macromolecular Symposia · doi:10.1002/masy.19910470130 · Cited by 35
Metadata
- Authors
- Ringsdorf, H.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Ringsdorf, Helmut
- Venue
- Journal of Polymer Science: Polymer Symposia
- Publisher
- Wiley
- Published
- 1975-01
- Volume
- 51
- Issue
- 1
- Pages
- 135-153
- ISSN
- 0360-8905 (ISSN-L)
- 1936-0959
- OpenAlex
- W2098279377
- Cited by
- 1,094
- References
- 63
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 34 · 2023: 35 · 2022: 30 · 2021: 35 · 2020: 50 · 2019: 36 · 2018: 29 · 2017: 46 · 2016: 45 · 2015: 47 · 2014: 55 · 2013: 43 · 2012: 48
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Polymer Science Polymer Symposia (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Advanced Polymer Synthesis and Characterization
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- macromolecular drugs, comonomer incorporation, polymer-analogous reactions, solubility, toxicity, body distribution, polymer synthesis, biological activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.